Also from this source

You just read:

Takeda Reports Top Line Results in Line With Guidance, With Underlying Growth of +2.8% EPS Affected by One-time Charges in FY2014 Back to Profitable Growth from FY2015 Onward

News provided by

Takeda Pharmaceutical Company Limited

May 15, 2015, 02:26 ET